Spectral Medical closes $14 million convertible notes offering

Spectral Medical completed a C$14.0 million private placement of convertible unsecured notes, including a C$6.3 million second tranche after a C$7.7 million first tranche closed October 30, 2026. The notes mature November 1, 2031, bear interest at CORRA plus 800 basis points, and are convertible at C$1.00 per unit; proceeds from the second tranche are for general corporate and working capital purposes. Spectral is pursuing U.S. FDA approval for its Toraymyxin device for septic shock.

Analysis

The financing reduces near-term funding pressure, but it is costly, floating-rate capital rather than evidence that Toraymyxin is closer to U.S. commercialization. CORRA + 800 bps, with cash interest or PIK at Spectral’s election, creates a meaningful balance-sheet sensitivity to rates and cash runway; PIK preserves liquidity now but compounds the claim on future value. The unsecured structure leaves noteholders exposed if clinical or regulatory progress disappoints.

There is also a defined equity overhang: full conversion of the $14 million principal would issue 14 million shares and 7 million warrants, before accrued interest; Paradigm separately received 315,000 compensation options. Without the current share count and price, the dilution percentage and whether conversion is economically likely cannot be assessed. A move toward $1 could make conversion more relevant, while warrant exercise requires a price above $1.10.

Near term, the raise may ease financing anxiety; over the next 1–3 months, the key checks are cash runway, burn, and any disclosed FDA or trial milestones—not the financing headline. Over 6–18 months, clinical/regulatory execution determines whether dilution buys valuable time or merely delays another capital raise. The contrarian risk is treating a completed raise as a de-risking event: proceeds are earmarked for working capital, and no runway extension or catalyst timing is quantified. No directional trade is justified without share count, cash/burn, market price, and borrow/liquidity data. The funding-risk concern would weaken materially with a credible FDA path and financing runway through key milestones; it strengthens if cash burn accelerates or milestones slip.

Key Decisions for Investors

• Do not buy EDT solely on the financing announcement. Treat it as near-term liquidity relief, not validation of the clinical thesis.
• Request the latest cash balance, quarterly burn, fully diluted share count, and expected timing/cost of remaining Phase 3 and FDA work before sizing equity exposure; these determine whether $14 million meaningfully bridges to a catalyst.
• Track the share price relative to the $1 conversion price and $1.10 warrant strike. A rally through those levels may improve financing flexibility but also increase potential dilution; below $1, assess whether the notes remain debt and whether another raise may be needed.
• Avoid an outright short absent verified borrow and liquidity. Reassess the negative funding-overhang thesis if Spectral reports runway through material FDA milestones or provides concrete, favorable trial/regulatory progress; intensify scrutiny if burn rises or milestones are delayed.